Clinical trial Recruiting at 1 site Interventional Ages 50 and up

Unipolar vs Bipolar Radiofrequency Ablation for Knee Osteoarthritis Pain

Official title: Unipolar Versus Bipolar Radiofrequency Ablation in Knee Osteoarthritis Pain: A Randomized Single-Blinded Trial

Run by Tanta University · NCT07789340 · Data updated 2026-11-12

This study tests whether unipolar or bipolar radiofrequency ablation provides better pain relief for adults over 50 with knee osteoarthritis who have not responded to other treatments.

More Knee Osteoarthritis trials

Quick facts

Study typeInterventional
Ages50 Years and up
SexAll
Enrollment64 (estimated)
SponsorTanta University
Academic / other
Locations1 site (Tanta, El-Gharbia)
StatusRecruiting
StartedAugust 29, 2026
Main results expectedJune 1, 2027
Study endsJune 1, 2027
Registry record updatedNovember 4, 2026
Trial IDNCT07789340 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults over 50 with chronic knee OA pain (Kellgren-Lawrence II-IV) who have not responded to standard treatments and have a positive diagnostic genicular block.

Probably not a fit

Patients with recent knee infection, active inflammatory disease, prior knee surgery, or contraindications to nerve ablation may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares two radiofrequency ablation techniques, unipolar and bipolar, to relieve chronic knee pain due to osteoarthritis. A diagnostic genicular nerve block is used to select participants likely to benefit, followed by nerve ablation using one of the two methods. Eligible participants are adults over 50 with radiographically confirmed knee OA (Kellgren-Lawrence II-IV) and persistent pain despite prior therapies. The study is conducted at Tanta University in Egypt with a lead sponsor and no listed collaborators. Outcomes focus on pain relief and function after the procedure, assessing whether the bipolar approach offers advantages over the unipolar approach.

Why it matters

Potential benefit: If successful, patients may experience greater and longer-lasting pain relief from knee OA with one ablation technique over the other.

How similar studies have gone: Prior data on genicular nerve RFA shows potential for pain reduction, but direct comparisons of unipolar versus bipolar approaches are limited, making this study relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age \> 50 years.
* Both genders.
* Diagnosed with chronic knee osteoarthritis (KOA) according to the American College of Rheumatology (ACR) criteria and confirmed with plain radiography as the gold standard for the diagnosis of KOA.
* One chronic KOA pain not responding to other treatments as physiotherapy, oral analgesics, and intraarticular injection with hyaluronic acids or steroids.
* Kellgren-Lawrence grade (II-IV).

Exclusion Criteria:

* Chronic knee pain induced by infection, inflammation, tumors, and fractures.
* Prior knee surgery.
* Acute knee pain.
* Connective tissue diseases.
* Neurologic or psychiatric disorders.
* Intra-articular knee corticosteroid or hyaluronic acids in the past 3 months.
* Anticoagulant medication.
* Local infection of the site of intervention.
* Cognitive impairment.

Where it's running

  • Tanta University
    Tanta, El-Gharbia, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.